GlassScriptPhysician profile
Billy R Mcbay
NPI 1659340826
$15,296.43
in general payments reported to CMS, 2019-2025
45 companies · $2,243 in 2025
The $2,243 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $1,780 · 2021: $2,849 · 2022: $2,235 · 2023: $3,008 · 2024: $2,715 · 2025: $2,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,966.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,435.62 | 2020-2025 | |
| Amgen INC. | $2,403.25 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Glaxosmithkline, LLC. | $1,800.03 | 2019-2025 | Trelegy Ellipta, Benlysta, Shingrix |
| Ucb, INC. | $1,674.45 | 2020-2025 | Cimzia, Bimzelx, Rystiggo |
| Mallinckrodt Hospital Products INC. | $745.18 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $699.01 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $553.70 | 2019-2025 | Jardiance, Taltz |
| Astrazeneca Pharmaceuticals LP | $545.73 | 2019-2025 | Farxiga, Airsupra, Saphnelo |
| Novo Nordisk INC | $519.77 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Biotech, INC. | $414.15 | 2021-2023 | Simponi Aria, Simponi, Stelara |
| Pfizer INC. | $312.61 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $238.59 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $200.18 | 2020-2023 | Spravato |
| Abbott Laboratories | $169.36 | 2021-2023 | Freestyle Libre |
| Insulet Corporation | $147.46 | 2021-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Billy Mcbay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.